Marketing Authorization Applications, Quarterly Dividends, Publication of Clinical Trial Data, Acquisitions, and Financial

  Marketing Authorization Applications, Quarterly Dividends, Publication of  Clinical Trial Data, Acquisitions, and Financial Results - Analyst Notes on                 Regeneron, Amgen, Sangamo, Alnylam, and Agios  Editor Note: For more information about this release, please scroll to bottom  PR Newswire  NEW YORK, March 11, 2014  NEW YORK, March 11, 2014 /PRNewswire/ --  Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Amgen, Inc. (NASDAQ: AMGN), Sangamo BioSciences, Inc. (NASDAQ: SGMO), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), and Agios Pharmaceuticals, Inc. (NASDAQ: AGIO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register  --  Regeneron Pharmaceuticals, Inc. Analyst Notes  On March 3, 2014, Regeneron Pharmaceuticals, Inc. (Regeneron) announced that Bayer Yakuhin, Ltd. (Bayer Yakuhin) - a subsidiary of Bayer HealthCare, has submitted an application for marketing authorization for EYLEA (aflibercept) Injection for the treatment of patients with diabetic macular edema (DME) to the Japanese Ministry of Health, Labour and Welfare (MHLW). "Clinically significant DME is a leading cause of vision loss in the working-age population suffering from diabetes. With increasing rates of diabetes worldwide, there continues to be a need for new treatment options," said George D. Yancopoulos, M.D., Ph. D., Chief Scientific Officer of Regeneron and President of Regeneron Laboratories. "We are pleased with this regulatory submission and hope that if approved, EYLEA will provide a new option for the treatment of DME in Japan." The full analyst notes on Regeneron Pharmaceuticals, Inc. are available to download free of charge at:  http://www.AnalystsReview.com/03112014/REGN/report.pdf  --  Amgen, Inc. Analyst Notes  On March 5, 2014, Amgen, Inc. (Amgen) announced that its Board of Directors has declared a dividend of $0.61 per share for Q2 2014. The Company informed that the dividend is payable on June 6, 2014, to all stockholders of record as of the close of business on May 15, 2014. The full analyst notes on Amgen, Inc. are available to download free of charge at:  http://www.AnalystsReview.com/03112014/AMGN/report.pdf  --  Sangamo BioSciences, Inc. Analyst Notes  On March 6, 2014, Sangamo BioSciences, Inc. (Sangamo) announced the presentation of data from its SB-728-T program to develop a 'functional cure' for HIV/AIDS at the Conference on Retroviruses and Opportunistic Infections (CROI 2014). In addition, the Company informed that data from an earlier Phase 1 clinical study in this program was also published in the March 6, 2014 issue of the New England Journal of Medicine (NEJM). "Our studies have generated valuable data that will enable us to maximize the potential of this novel immunologic therapy for HIV and help optimize patient selection and treatment," said Geoff Nichol, M.B., Ch.B., Executive Vice President of Research and Development at Sangamo. Edward Lanphier, President and CEO of the Company, added, "In the next clinical trial of SB-728-T, which is expected to begin in the first half of 2014, we will implement mRNA delivery of the ZFNs to the cells, which will provide both process- and cost-saving advantages over viral delivery as well as the potential to re-dose." The full analyst notes on Sangamo BioSciences, Inc. are available to download free of charge at:  http://www.AnalystsReview.com/03112014/SGMO/report.pdf  --  Alnylam Pharmaceuticals, Inc. Analyst Notes  On March 6, 2014, Alnylam Pharmaceuticals, Inc. (Alnylam) announced the closing of the previously announced acquisition of Merck's wholly owned subsidiary Sirna Therapeutics, Inc. (Sirna), post the expiration of the Hart-Scott-Rodino waiting period. In consideration for the Sirna common stock, Alnylam has paid Merck $25.0 million in cash and has agreed to issue to Merck 2.5 million shares of Alnylam common stock with a value of $150.0 million. Commenting on this acquisition, John Maraganore, Ph.D., CEO of Alnylam said, "Further, we believe our acquisition of Merck's RNAi assets and Sirna subsidiary supports Alnylam's continued leadership on RNAi intellectual property and delivery, including with GalNAc conjugate technology." The full analyst notes on Alnylam Pharmaceuticals, Inc. are available to download free of charge at:  http://www.AnalystsReview.com/03112014/ALNY/report.pdf  --  Agios Pharmaceuticals, Inc. Analyst Notes  On March 6, 2014, Agios Pharmaceuticals, Inc. (Agios) reported its Q4 2013 and full-year 2013 financial results. In Q4 2013, the Company's revenues totalled $6.7 million, up 7.4% YoY, while full-year 2013 revenues totalled $25.5 million, up 1.8% YoY. Q4 2013 net loss applicable to common stockholders was $12.4 million, or $0.40 loss per share, compared to a net loss of $7.1 million, or $2.09 loss per share, in Q4 2012. Full-year 2013 net loss applicable to common stockholders was $43.6 million, or $2.83 loss per share, compared to a net loss of $27.3 million, or $8.02 loss per share, for full-year 2012. "In 2013, we continued to apply our scientific and clinical leadership in the field of cellular metabolism towards our goal of transforming the lives of patients with cancer and inborn errors of metabolism," said David Schenkein, M.D., CEO of Agios. "We successfully filed two investigational new drug applications, or INDs, for novel first-in-class therapeutic candidates and completed IND activities for our third program. In early 2014, we continue to make important progress across our pipeline." The full analyst notes on Agios Pharmaceuticals, Inc. are available to download free of charge at:  http://www.AnalystsReview.com/03112014/AGIO/report.pdf  --  About Analysts Review We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.  --  =============  EDITOR NOTES:    oThis is not company news. We are an independent source and our views do     not reflect the companies mentioned.   oInformation in this release is fact checked and produced on a best efforts     basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are     only human and are prone to make mistakes. If you notice any errors or     omissions, please notify us below.   oThis information is submitted as a net-positive to companies mentioned, to     increase awareness for mentioned companies to our subscriber base and the     investing public.   oIf you wish to have your company covered in more detail by our team, or     wish to learn more about our services, please contact us at pubco [at]     AnalystsReview.com.   oFor any urgent concerns or inquiries, please contact us at compliance [at]     AnalystsReview.com.   oAre you a public company? Would you like to see similar coverage on your     company? Send us a full investors' package to research [at]     AnalystsReview.com for consideration.  COMPLIANCE PROCEDURE  Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.  NOT FINANCIAL ADVICE  Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.  NO WARRANTY OR LIABILITY ASSUMED  Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.  CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.  SOURCE Analysts Review  Contact: Adam Redford CONTACT PHONE: +852-8191-3972  
Press spacebar to pause and continue. Press esc to stop.